SEC Form 4 · accession 0001209191-15-084559

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Dec 9, 2015

Accepted (ET)

Dec 11, 2015 · 8:43 am EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Dec 9, 2015	M	10,400	$35.64	A	275,684	D
Common Stock^F2,F3	Dec 9, 2015	S	5,800	$120.24	D	269,884	D
Common Stock^F2,F4	Dec 9, 2015	S	3,090	$121.07	D	266,794	D
Common Stock^F2,F5	Dec 9, 2015	S	810	$122.11	D	265,984	D
Common Stock^F2,F6	Dec 9, 2015	S	700	$122.74	D	265,284	D
Common Stock	holding	—	—		—	13,286	I	401k
Common Stock	holding	—	—		—	122,700	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F7	$35.64	Dec 9, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	73,600	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $120.24 (range $119.52 to $120.51).
F4Open market sales reported on this line occurred at a weighted average price of $121.07 (range $120.52 to $121.51).
F5Open market sales reported on this line occurred at a weighted average price of $122.11 (range $121.52 to $122.38).
F6Open market sales reported on this line occurred at a weighted average price of $122.74 (range $122.55 to $122.85).
F7Fully vested.